Sanofi – Stilnoct
Heavy competition from generic products was expected with a looming patent expiry in the UK, so a new breath of life was needed to revive the products positioning with UK GPs in order to prevent sales figures from nodding off!
Some of the outcomes were:
- 600% return on Investment (ROI)
- 24% response to 42,000 UK GP mailing list
- 4 marketing awards including Royal Mail DMA & PM award